Engineered extracellular vesicles for ischemic heart diseases: modification methods, targeted delivery strategies, and multi-modal therapies - A systematic review - Top-Institutions - MDSpire

Engineered extracellular vesicles for ischemic heart diseases: modification methods, targeted delivery strategies, and multi-modal therapies - A systematic review

  • By

  • Sha Su

  • Yu Teng

  • Shaojiao Liu

  • Lei Wang

  • Mingjing Zhao

  • June 18, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Cedars-Sinai Medical Center
    Cedars-Sinai Medical Center

    Los Angeles, California

    Key Differentiators

    • Cardiology
    • Heart & Vascular Surgery

  • #2

    Stanford Health Care/Stanford University School of Medicine
    Stanford Health Care/Stanford University School of Medicine

    Stanford, California

    Key Differentiators

    • Cardiology
    • Heart & Vascular Surgery

Original Source(s)

Engineered extracellular vesicles for ischemic heart diseases: modification methods, targeted delivery strategies, and multi-modal therapies - A systematic review

  • by Sha Su, Yu Teng, Shaojiao Liu, Lei Wang, Mingjing Zhao

  • June 18, 2026

Related Content

Hoxb4 upregulation by Xuan Bi Tong Yu Fang confers cardioprotection via repression of the Wnt/β-catenin pathway in myocardial ischemia-reperfusion injury

Progressive Aortic Regurgitation and Persistent Atrial Fibrillation in a Case of Bilateral Coronary Artery Fistulas Complicated by Acute Heart Failure and Pulmonary Hypertension

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.